Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry
2006; 60: 369–375.
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry
2004; 61: 1136–1144.
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry
2008; 63: 1118–1126.
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry
2008; 165: 335–341.
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry
2010; 68: 1073–1076.
Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res
2013; 47: 168–174.
Children's Yale–Brown Obsessive–Compulsive Scale: realiability and validity. J Am Acad Child Adolesc Psychiatry
1997; 36: 844–852.
Anxiety Disorders Interview Schedule for Children – IV, Child and Parent Versions. Psychological Corporation, 1996.
Development of a patient adherence scale for exposure and response prevention therapy. Behav Ther
2010; 41: 30–37.
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Adolesc Psychiatry
2004; 43: 1488–1496.
Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med
1997; 16: 2349–2380.
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther
2010; 48: 675–679.
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol
2007; 22: 230–237.